SLIT-2-N human,;, recombinant, expressed in HEK 293 cells, >=98% (SDS-PAGE), >=98% (HPLC), cell culture tested

Code: srp3155-200ug D2-231

Not available outside of the UK & Ireland.

Application

Slit guidance ligand 2 (SLIT-2) has been used to treat cells in podocyte culture and in myosin II regulatory light chain (MRLC) phosphorylation assay.


read more

Your Price
$2,707.12 EACH

Not available outside of the UK & Ireland.

Application

Slit guidance ligand 2 (SLIT-2) has been used to treat cells in podocyte culture and in myosin II regulatory light chain (MRLC) phosphorylation assay.

Biochem/physiol Actions

Slit guidance ligand 2 (SLIT-2) acts as a repellent for axon guidance and neuronal migration, and it can also act as a chemoattractant to vascular endothelial cells and a chemotaxis inhibitor for leukocytes. It prevents the migration of T cells, neutrophils and macrophages, but enhances eosinophil migration. The protein has been shown to be downregulated in cancers.

General description

Slit guidance ligand 2 (SLIT-2) is a member of the Slit family that signals through the Roundabout (Robo) receptor. It is also referred to as SLIL3. SLIT2 is expressed primarily in the fetal lung, kidney, and adult spinal cord, and to a lesser extent in adult adrenal gland, thyroid and trachea. It is initially synthesized as a 1499 amino acid precursor, which is subsequently cleaved into N-terminal and C-terminal fragments, designated as Slit2-N and Slit2-C respectively. The neurodevelopment related activities, as measured by the ability to repel olfactory bulb axons and to induce branching in dorsal root ganglia axons, are contained only in the N-terminal fragment. Recombinant human Slit2-N is a 1093 amino acid glycoprotein corresponding to the N-terminal portion of the full length Slit2 precursor. Due to glycosylation Slit2-N migrates at an apparent molecular weight of approximately 120.0-140.0kDa by SDS-PAGE analysis under reducing conditions.

Physical form

Lyophilized from 20 mM Tris + 200 mM L-Arginine, pH 8.8.

Reconstitution

Centrifuge the vial prior to opening. Reconstitute in 20mM Tris, pH 8.8 + 150mM NaCl to a concentration of 0.1-1.0mg/ml. Note: Slow to dissolve. Do not vortex. This solution can be stored at 2-8°C for up to 1 week. For extended storage, it is recommended to further dilute in a buffer containing a carrier protein (example 0.1% BSA) and store in working aliquots at -20°C to -80°C.

Sequence

QACPAQCSCS GSTVDCHGLA LRSVPRNIPR NTERLDLNGN NITRITKTDF AGLRHLRVLQ LMENKISTIE RGAFQDLKEL ERLRLNRNHL QLFPELLFLG TAKLYRLDLS ENQIQAIPRK AFRGAVDIKN LQLDYNQISC IEDGAFRALR DLEVLTLNNN NITRLSVASF NHMPKLRTFR LHSNNLYCDC HLAWLSDWLR QRPRVGLYTQ CMGPSHLRGH NVAEVQKREF VCSGHQSFMA PSCSVLHCPA ACTCSNNIVD CRGKGLTEIP TNLPETITEI RLEQNTIKVI PPGAFSPYKK LRRIDLSNNQ ISELAPDAFQ GLRSLNSLVL YGNKITELPK SLFEGLFSLQ LLLLNANKIN CLRVDAFQDL HNLNLLSLYD NKLQTIAKGT FSPLRAIQTM HLAQNPFICD CHLKWLADYL HTNPIETSGA RCTSPRRLAN KRIGQIKSKK FRCSAKEQYF IPGTEDYRSK LSGDCFADLA CPEKCRCEGT TVDCSNQKLN KIPEHIPQYT AELRLNNNEF TVLEATGIFK KLPQLRKINF SNNKITDIEE GAFEGASGVN EILLTSNRLE NVQHKMFKGL ESLKTLMLRS NRITCVGNDS FIGLSSVRLL SLYDNQITTV APGAFDTLHS LSTLNLLANP FNCNCYLAWL GEWLRKKRIV TGNPRCQKPY FLKEIPIQDV AIQDFTCDDG NDDNSCSPLS RCPTECTCLD TVVRCSNKGL KVLPKGIPRD VTELYLDGNQ FTLVPKELSN YKHLTLIDLS NNRISTLSNQ SFSNMTQLLT LILSYNRLRC IPPRTFDGLK SLRLLSLHGN DISVVPEGAF NDLSALSHLA IGANPLYCDC NMQWLSDWVK SEYKEPGIAR CAGPGEMADK LLLTTPSKKF TCQGPVDVNI LAKCNPCLSN PCKNDGTCNS DPVDFYRCTC PYGFKGQDCD VPIHACISNP CKHGGTCHLK EGEEDGFWCI CADGFEGENC EVNVDDCEDN DCENNSTCVD GINNYTCLCP PEYTGELCEE KLDFCAQDLN PCQHDSKCIL TPKGFKCDCT PGYVGEHCDI DFDDCQDNKC KNGAHCTDAV NGYTCICPEG YSGLFCEFSP PMV

assay≥98% (SDS-PAGE), ≥98% (HPLC)
biological sourcehuman
colorwhite
formlyophilized
Gene Informationhuman ... SLIT2(9353)
impurities﹤0.1 EU/µg endotoxin, tested
mol wt120.0-140.0 kDa
packagingpkg of 25 µg, pkg of 200 µg
recombinantexpressed in HEK 293 cells
shipped inwet ice
storage temp.−20°C
technique(s)cell culture | mammalian: suitable
UniProt accession no.O94813
Code
Description
Unit Size
List Price
Qty
This product has met the following criteria: